<DOC>
	<DOCNO>NCT03039790</DOCNO>
	<brief_summary>The purpose study evaluate descriptively long-term immunogenicity least 1 Norovirus GI.1/GII.4 bivalent VLP vaccine ( NoV ) vaccine administration .</brief_summary>
	<brief_title>Long-Term Immunogenicity Norovirus GI.I/GII.4 Bivalent Virus-Like Particle ( VLP ) Vaccine Adults</brief_title>
	<detailed_description>The drug test study call Norovirus GI.1/GII.4 bivalent Virus-Like Particle Vaccine ( NoV Vaccine ) . NoV vaccine test protection acute gastroenteritis ( AGE ) due norovirus . The study enroll approximately 800 participant . Participants previously receive NoV vaccine study NOR-107 , NOR-210 , NOR-204 NOR-222 enrol . Participants study NOR-107 enter study time 3rd year post-primary vaccination , study NOR-210 NOR-204 , 2nd year post-primary vaccination , study NOR-222 , time 1st year post-primary vaccination . The duration participation study different participant . This multi-center trial conduct Belgium United States . The overall time participate study maximum 5 year primary NoV vaccination . Participants maximum 5 visit 5 year .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Male female participant previously receive least 1 dose Norovirus GI.1/GII.4 bivalent VLP ( NoV ) vaccine trial NOR107 , NOR210 , NOR204 NOR222 , baseline postvaccination data , complete primary vaccination trial protocol initially describe . 1 . Participation clinical trial allow , condition investigational product administer within 30 day prior blood sampling . 2 . In opinion investigator , participant medically eligible provide blood specimen . 3 . Individuals behavioral cognitive impairment psychiatric disease , opinion investigator , may interfere participant 's ability participate trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Immunogenicity , Norovirus vaccination</keyword>
</DOC>